Last update:

Weight management news

GLP-1 use among young children with obesity in US remains rare but is rising rapidly

Although the number of U.S. children under age 12 with obesity who are prescribed the weight-loss drugs Saxenda, Wegovy and Zepbound remains low, it was 310 times higher in June 2026 than in 2019, when the drugs were first ...

Experts say restricting junk food ads on public transport would pay off

Ever craved fast food after seeing an enticing ad on a bus or at a train station? Such powerful advertisements increase consumption of unhealthy foods and drinks, contributing to obesity, which costs Australia's health care ...

Some hair loss in men is linked to weight loss drug use

Men already genetically at risk for the most common form of hair loss have a 7% added risk of losing their hair if they use drugs like Ozempic, Wegovy and Zepbound for type 2 diabetes and obesity, a new study shows.

Why men can struggle with weight-loss initiatives

A new study has identified why many men struggle with weight loss, finding that traditional diet programs are often perceived as too restrictive and primarily aimed at women. The research, published in PLOS One and led by ...

GLP-1 meds prompt rethink of obesity and eating disorder care

Obesity and eating disorders have traditionally been treated as separate areas of health care—but the rapid rise of GLP-1 medicines is increasingly bringing the two together. Adelaide University researchers say the growing ...